IP Library Granted Patent US 10,668,040
Granted Patent B2
US 10,668,040 · App. 16/128,140 · Granted Jun 2, 2020

Treatment of urea cycle disorders in neonates and infants

Inventors: Bruce Scharschmidt (San Francisco, CA); Masoud Mokhtarani (Walnut Creek, CA)
Assignee: Horizon Therapeutics, LLC
A61K31/216A61K9/0053A61K9/0095G01N33/84G01N2800/52G01N2800/708
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,040
App. No.
16/128,140
Granted
Jun 2, 2020
Kind
B2
Abstract

Nitrogen scavenging drugs such as glycerol phenylbutyrate can be administered safely to infants and toddlers with urea cycle disorders by adjusting the dosage based on one or more biomarkers selected from the group consisting of urinary-PAGN and plasma PAA:PAGN ratio.

Claims (24)

1. A method of treating a urea cycle disorder (UCD) in a patient under 2 years of age comprising

administering glycerol phenylbutyrate to said patient at an initial daily dose which is administered at an initial frequency of administration; and

if after said administration, said patient exhibits neurological symptoms, normal ammonia levels, and a ratio of plasma PAA to plasma PAGN of >2.5 or a level of plasma PAA of >500 μg/mL, then administering said glycerol phenylbutyrate to said patient at a reduced daily dose while maintaining said initial frequency of administration,

wherein the initial frequency of administration is 3 to 6 times daily, and

wherein if said patient is in a hyperammonemic crisis, then said initial daily dose is 11.2 mL/m 2 /day, if said patient is not in a hyperammonemic crisis, then said initial daily dose is 8.5 mL/m 2 /day, and if said patient previously had been administered NaPBA or NaBz, then said initial daily dose is equal to 0.81 times the total number of grams of NaPBA powder the patient was receiving, or 0.86 times the total number of grams of in NaPBA tablet form the patient was receiving, or 0.5 times the total number of grams of in NaBz the patient was receiving.

2. A method of treating a urea cycle disorder (UCD) in a patient under 2 years of age comprising

administering glycerol phenylbutyrate to said patient at an initial daily dose which is administered at an initial frequency of administration; and

if after said administration said patient exhibits neurological symptoms, normal ammonia levels, and a ratio of plasma PAA to plasma PAGN of >2.5 or a level of plasma PAA of >500 μg/mL, then administering said glycerol phenylbutyrate to said patient at a lower dose or increased frequency of administration while maintaining said daily dose,

wherein the initial frequency of administration is 3 to 6 times daily, and

wherein if said patient is in a hyperammonemic crisis, then said initial daily dose is 11.2 mL/m 2 /day, if said patient is not in a hyperammonemic crisis, then said initial daily dose is 8.5 mL/m 2 /day, and if said patient previously had been administered NaPBA or NaBz, then said initial daily dose is equal to 0.81 times the total number of grams of NaPBA powder the patient was receiving, or 0.86 times the total number of grams of in NaPBA tablet form the patient was receiving, or 0.5 times the total number of grams of in NaBz the patient was receiving.

3. A method of treating a urea cycle disorder (UCD) in a patient under 2 years of age comprising

administering glycerol phenylbutyrate to said patient at an initial daily dose which is administered at an initial frequency of administration; and

if after said administration said patient exhibits neurological symptoms, normal ammonia levels, and a ratio of plasma PAA to plasma PAGN of <2.5, then said glycerol phenylbutyrate to said patient should continue to be administered at the same dose and frequency and the patient evaluated for other causes of his or her neurological symptoms,

wherein the initial frequency of administration is 3 to 6 times daily, and

wherein if said patient is in a hyperammonemic crisis, then said initial daily dose is 11.2 mL/m 2 /day, if said patient is not in a hyperammonemic crisis, then said initial daily dose is 8.5 mL/m 2 /day, and if said patient previously had been administered NaPBA or NaBz, then said initial daily dose is equal to 0.81 times the total number of grams of NaPBA powder the patient was receiving, or 0.86 times the total number of grams of in NaPBA tablet form the patient was receiving, or 0.5 times the total number of grams of in NaBz the patient was receiving.

4. The method of claim 1 , wherein said patient is less than about one month of age.

5. The method of claim 1 , wherein said patient is from 1 month to two years of age.

6. The method of claim 1 , wherein said neurological symptoms include headache, confusion, vomiting, lethargy, or any combination thereof.

7. The method of claim 2 , wherein said patient is less than about one month of age.

8. The method of claim 2 , wherein said patient is from 1 month to two years of age.

9. The method of claim 2 , wherein said neurological symptoms include headache, confusion, vomiting, lethargy, or any combination thereof.

10. The method of claim 3 , wherein said patient is less than about one month of age.

11. The method of claim 3 , wherein said patient is from 1 month to two years of age.

12. The method of claim 3 , wherein said neurological symptoms include headache, confusion, vomiting, lethargy, or any combination thereof.

Assignments (4)
MERGER AND CHANGE OF NAME Recorded Dec 21, 2023
From: HORIZON THERAPEUTICS, LLC; HORIZON ORPHAN LLC
To: HORIZON THERAPEUTICS U.S. HOLDING LLC
Reel/Frame 065928/0608 →
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2023
From: CITIBANK, N.A.
To: HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA HORIZON ORPHAN LLC); HZNP LIMITED; HORIZON THERAPEUTICS U.S. HOLDING LLC (SUCCESSOR IN INTEREST TO HORIZON THERAPEUTICS, LLC)
Reel/Frame 065154/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2021
From: SCHARSCHMIDT, BRUCE; MOKHTARANI, MASOUD
To: HORIZON THERAPEUTICS, LLC
Reel/Frame 056362/0613 →
SECURITY AGREEMENT Recorded Aug 17, 2020
From: HORIZON ORPHAN LLC; HORIZON THERAPEUTICS, LLC; HZNP LIMITED
To: CITIBANK, N.A.
Reel/Frame 053515/0273 →